Management of advanced gastric or gastroesophageal cancer in England
Research type
Research Study
Full title
A longitudinal study exploring the characteristics, treatment pathway and healthcare resource use of patients with advanced gastric or gastroesophageal junction cancer in England
IRAS ID
326433
Contact name
Vincent Angeloni
Contact email
Sponsor organisation
Astellas
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
Gastric cancer (GC) is a cancer which affects the stomach or the end of the oesophagus with a survival rate of only 22% within five years after diagnosis in the UK. Approximately 90% of detected gastric cancers are a subtype called adenocarcinomas. It is usually diagnosed via endoscopy and can be treated with a combination of surgery and chemotherapy. In early stages, gastric cancer can be treated with surgery in combination with chemotherapy. Overall, gastric tumours respond well to chemotherapy, but neoadjuvant chemotherapy remains the exception as it can delay a radical resection in early stages. Overall, biomarker testing in GC patients remains uncommon, thereby preventing more targeted therapies.
For this study, we will use the National Cancer Registry (NCR) to identify all patients in England diagnosed with GC between January 2013 and December 2019 with the overall aim of describing who is diagnosed with GC, their characteristics and their treatment journey. A combination of the systemic anti-cancer therapy dataset and the radiotherapy dataset, Hospital Episode Statistics, and Office for National Statistics death registry will be used to measure survival, what health care services patients used, and to describe different treatments patients receive. Finally, we will estimate the use and the associated costs for the health care services used.
This study will help to better understand the burden of gastric cancer in the UK, the profile of patients with this diagnosis, their clinical management and impact on the health care system. This research can inform future clinical management of people living with GC in the UK.
REC name
North East - Tyne & Wear South Research Ethics Committee
REC reference
23/NE/0189
Date of REC Opinion
13 Oct 2023
REC opinion
Favourable Opinion